Intelligence Platform
Clinical trials, SEC filings,
hedge fund positioning,
and how they connect.
One database, organized by company, updated daily from primary sources. Built for BD, investors, and strategy teams.
$499/mo
Cancel anytime. Access continues through the end of the billing period.
Live Platform Data
On the platform right now, from primary sources.
Updated Jul 6, 2026
Endpoint modifications, enrollment shifts, and status changes detected automatically for every registered trial.
Primary endpoint: Overall Response Rate → Progression-Free Survival
Status: Recruiting → Active, not recruiting
Enrollment: 45 → 120
Hedge fund ownership disclosures: who's building positions, reducing stakes, or going activist. Cross-referenced with trial events and 8-Ks.
TANG CAPITAL MANAGEMENT LLC
GordonMD Global Investments LP
Lynx1 Capital Management LP
8-K filings classified by type: licensing deals, FDA actions, financing events, and strategic reviews, identified automatically.
Jade Biosciences, Inc. entered into a worldwide, exclusive, royalty-bearing license agreement with Paragon Therapeutics, Inc. for monospecific antibodies targeting an undisclosed target for human diseases. The agreement includes up to $22.0 million in development and regulatory milestones, with a $1.5 million fee already paid for development candidate nomination and a $2.5 million milestone due upon first patient dosing in a Phase 1 trial. Jade will also pay low to mid-single-digit royalties on net sales.
Pfizer is reaffirming its fiscal year 2026 financial guidance, including projected revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS in the range of $2.80 to $3.00. This reaffirmation follows the disclosure of a Chief Financial Officer transition announcement and aligns with previously issued guidance.
Genprex announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 or PD-L1 antibodies for non-small cell and small cell lung cancer. This patent strengthens the company's intellectual property portfolio, providing crucial protection for therapeutic combinations currently being evaluated in the Acclaim-3 clinical trial. This expands on previously granted patents for REQORSA in other major markets.
All items link to original SEC documents and registry records on the platform.
Data
Primary sources, all linked.
Every data point traces to the original filing or registry record. No news, no analyst commentary, no third-party data vendors.
ClinicalTrials.gov
450K+ trials. Status, enrollment, endpoints, results, and change tracking. Updated daily.
SEC EDGAR
8-K, 10-K, 10-Q, Form 4, 13D/13G, 13F and more. Parsed and classified. Updated multiple times daily.
Financial Data
Filter companies by market cap, cash, expenses, and more for 500+ biotech companies.
FDA Data
Drug products, patent listings, and exclusivity records. Integrated
app.rxdatalab.com
What you can do
Built for BD, investors, and strategy teams who work from primary sources rather than news and analyst commentary.
Track a company across every source
Trial pipeline, 8-Ks, Regulatory filings, and financials in one view. Every item links to the original source document or registry record.
Monitor trial changes automatically
Daily comparison against ClinicalTrials.gov catches endpoint modifications, enrollment changes, arm updates, and status shifts. Nothing buried in the registry.
See who's building positions in biotech
Fund profiles with full position history and filing records. Multi-fund convergence on the same company. 13D/G cross-referenced with 8-K events and trial milestones.
See live data sample →Search SEC filings by what they mean
8-K filings classified into financing events, FDA actions, clinical results, licensing deals, and strategic reviews. Search by company, date range, or filing type, not just keyword.
See live data sample →Map competitive landscapes
Search by indication and surface every company running trials for that indication or related indications. Overlay financial position and recent trial events across the competitive field.
Organize research with projects and notes
Create projects with company and trial watchlists. Add timestamped notes directly on company and trial pages. Dashboard shows what changed across your coverage since your last session.
Data In Context
Every event, in context.
Financing events, licensing deals, trial changes, and hedge fund moves — overlaid on the quarterly financial timeline for Solid Biosciences Inc. (SLDB). Toggle layers, hover annotations, click any event to see the original source.
Competitive Landscape
Explore the competitive biotech landscape.
Search any indication. We map every industry trial using the NLM's MeSH medical ontology, then overlays institutional ownership, financial position, and recent trial events across the competitive field.
Condition Landscape
Active industry trials per condition. Search any condition on the platform.
Active Sponsors
| Company | Mkt Cap | Trials | Cash | Qtr Exp |
|---|---|---|---|---|
| Cullinan Therapeutics, Inc. CGEM | $1.1B | 1 | $75M | $54M |
| C4 Therapeutics, Inc. CCCC | $475M | 3 | $61M | $34M |
| Autolus Therapeutics plc AUTL | $420M | 1 | $131M | $61M |
| Karyopharm Therapeutics Inc. KPTI | $218M | 2 | $91M | $60M |
| Caribou Biosciences, Inc. CRBU | $180M | 2 | $12M | $29M |
| Senti Biosciences, Inc. SNTI | $33M | 1 | $12M | $12M |
| Cellectar Biosciences, Inc. CLRB | $22M | 1 | $8M | $6M |
| GeoVax Labs, Inc. GOVX | $6M | 1 | $1M | $5M |
Sample data. Financial data from parsed 10-K/Q filings. Qtr Exp = R&D + G&A per quarter.
Pricing
Simple, transparent pricing.
Individual — Monthly
Billed monthly. Cancel anytime from your account page.
- ✓ Full platform access
- ✓ BioHedge (13D/G fund positioning)
- ✓ Clinical trial change detection
- ✓ 8-K signal detection
- ✓ Competitive landscape mapping
- ✓ Research workspace and notes
Teams & Institutions
Custom pricing
For teams, firms, and institutional users who need multi-seat access, custom coverage, AI Access, API Access, or enterprise billing.
- ✓ Multi-seat access
- ✓ Custom data coverage and exports
- ✓ Invoiced billing and enterprise contracts
- ✓ API access and custom data feeds
- ✓ Dedicated support
What happens after payment?
You'll receive a welcome email with a link to set your password. Access immediately once your password is set.
How do I cancel?
Go to your account page and click "Manage Billing." Access continues through the end of your billing period.
Do you offer trials or demos?
The public pages at app.rxdatalab.com/biohedge and app.rxdatalab.com/strategic-signals show live data and require no login.
Questions or enterprise pricing?
Email [email protected] for team access, institutional pricing, or anything else.
By subscribing you agree to our Terms of Service and Data License Agreement.